Depo-Provera Meningioma Lawsuit: What You Need to Know About MDL 3140 in 2026

The Depo-Provera meningioma litigation is one of the fastest-growing pharmaceutical MDLs in the federal court system right now. If you or someone you care for used Depo-Provera for an extended period and later received a meningioma diagnosis, this post explains what the litigation is, what plaintiffs are actually claiming, what Pfizer’s defense looks like, and what the realistic near-term timeline is.

I’ll be direct about what is verified and what is still unresolved.

What Depo-Provera Is and Who Used It

Depo-Provera is a brand name for injectable medroxyprogesterone acetate (MPA), a synthetic progestin used as a contraceptive. It is administered as a shot every three months, which made it popular for patients who preferred not to manage a daily pill. It has been prescribed in the United States for decades and was widely used across age groups, including adolescents.

The active compound — medroxyprogesterone acetate — is a progestogen. High-dose, long-duration progestogen exposure has been studied in relation to benign meningioma formation in other contexts, particularly with certain oral progestins used in Europe. The 2024 BMJ study extended this line of inquiry specifically to injectable MPA.

The Science Behind the Claims

The foundational study driving this litigation was published in BMJ in early 2024 by French researchers using national health data. Their case-control design found that women who used Depo-Provera for one year or more had approximately a 5.55-fold increased risk of developing an intracranial meningioma compared to non-users.

That number sounds alarming, and it is what made headlines. The full picture is more nuanced: the researchers estimated that the absolute additional risk translated to roughly five additional meningioma cases per 10,000 long-term users. The injectable-form cohort was also relatively small within the study population. The authors themselves flagged these limitations.

None of that makes the research invalid. It does mean the litigation is fighting over the interpretation of relative versus absolute risk, the study’s methodology, and whether any increased risk was knowable to Pfizer at what point in time. These are the battles that will play out in the bellwether trial.

Understanding how pharmaceutical MDLs work — mesothelioma litigation context →

MDL 3140: The Litigation Structure

The case is formally titled In re: Depo-Provera Products Liability Litigation, MDL No. 3140, and it sits in the United States District Court for the Northern District of Florida, presided over by Judge M. Casey Rodgers. The MDL was established in 2025.

As of May 2026, approximately 3,769 cases are pending. The docket has grown steadily as plaintiff attorneys who handle mass tort litigation have been advertising nationally following the 2024 BMJ publication.

Defendants named in the litigation include Pfizer (the primary defendant), Pharmacia & Upjohn (a Pfizer predecessor), A-S Medication Solutions, and Preferred Pharmaceuticals. Several generic manufacturers were named in some cases but have been dismissed in others — generic manufacturer liability in pharmaceutical cases is governed by a different legal standard under Pliva v. Mensing.

What Plaintiffs Are Alleging

The core legal theories are:

Failure to warn — Plaintiffs allege that Pfizer knew or should have known about the association between long-term Depo-Provera use and meningioma risk, and failed to disclose this adequately to prescribing physicians and patients. This is the primary theory across most cases. It is an allegation; causation and knowledge timing have not been legally established.

Defective design — Some plaintiffs allege that alternative formulations could have provided the same contraceptive benefit with lower meningioma risk. This theory is more legally complex and is not universal across all filed cases.

Legal Theory	Core Question
Failure to warn	Did Pfizer know the risk and fail to disclose it?
Defective design	Was there a safer alternative available?
Negligence	Did Pfizer fall below the standard of care?

Pfizer’s Defense — Federal Preemption Weakened

Pfizer’s principal defense throughout 2025 was federal preemption. The argument goes: FDA regulations govern what a pharmaceutical company can put on its label; if the FDA reviewed and declined a stronger warning, then state tort law cannot independently require that same warning through a damages verdict. This is derived from the Supreme Court’s framework in Wyeth v. Levine and its progeny.

The specific wrinkle here was that Pfizer reportedly sought FDA approval for a stronger label and was turned down. That history, if accurate, would have been a significant preemption argument.

Then, in December 2025, the FDA approved updated Depo-Provera labeling that includes a meningioma warning. That decision gutted the preemption defense. The FDA’s own action confirmed that the warning was warranted — making it very difficult for Pfizer to continue arguing that adding such a warning was impermissible. This is arguably the most significant litigation development to date.

Eligibility: Who Fits the Profile

Attorneys evaluating these cases generally look at the following factors. This is not a determination of eligibility — that requires individual legal analysis:

• Use of Depo-Provera (brand or generic injectable MPA) for approximately one year or more
• Diagnosis of intracranial meningioma
• Temporal relationship between use and diagnosis
• Statutes of limitations: most states give plaintiffs two to four years from the date of diagnosis, not from the date of use

If you were diagnosed with meningioma and have a history of Depo-Provera use, consulting a mass tort attorney sooner rather than later is advisable. Initial consultations are typically free, and these cases are handled on contingency.

What happens after a pharmaceutical settlement — structured payments explained →

Timeline: December 2026 Is the Pivot Point

Mass tort MDLs follow a predictable arc. Discovery is completed across a group of representative cases. A few of those cases are selected as bellwether trials — early test cases that give both sides, their experts, and the court a concrete data point on how juries respond to the evidence.

In MDL 3140, the first bellwether trial is scheduled for December 2026. This is a critical event. A plaintiff verdict would almost certainly accelerate settlement discussions across the remaining 3,000+ cases. A defense verdict would significantly reduce settlement pressure on Pfizer.

No settlement amounts have been established or announced. Any specific figures you see quoted online at this stage are speculative. The litigation is too early for reliable settlement estimates.

What to Do Now

1. Document your use history — Locate any records of Depo-Provera injections: dates, prescribing provider, clinic. Even if formal records are incomplete, pharmacy records and insurance Explanation of Benefits documents can help establish duration.
2. Obtain your diagnostic records — Pathology report confirming meningioma, MRI reports, surgical records if applicable.
3. Check your state’s statute of limitations — Most run two to four years from diagnosis date. A plaintiff attorney can tell you exactly what applies in your state in the first consultation.
4. Do not wait to consult an attorney — Mass tort firms handling MDL 3140 work on contingency. There is no upfront cost to getting a case evaluation.

Ovarian cancer litigation context for pharmaceutical failure-to-warn cases →

Hernia mesh litigation — another large pharmaceutical MDL for context →

The December 2026 bellwether trial is approximately six months away. The litigation is real, the MDL is established, and the FDA has now formally acknowledged the meningioma risk. What remains unresolved is valuation — and that is what the next twelve months will begin to establish.

This post is for informational purposes only and does not constitute legal advice. Consult a licensed attorney in your state for guidance specific to your situation.